Vanda Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Vanda Pharmaceuticals Inc. is developing treatments for schizophrenia by rescuing previously discontinued compounds and developing them into individualized therapeutics through the use of pharmacogenomics and pharmacogenetics.
You may also be interested in...
Phase III Data Support Premium Pricing For Vanda’s Sleep Drug Tasimelteon
Vanda anticipates that if approved, its drug for the rare “non-24-hour” circadian rhythm disorder will command pricing in line with orphan disease treatments. Second Phase III trial has it on track for a mid-2013 submission.
Phase III Data Support Premium Pricing For Vanda’s Sleep Drug Tasimelteon
Vanda anticipates that if approved, its drug for the rare “non-24-hour” circadian rhythm disorder will command pricing in line with orphan disease treatments. Second Phase III trial has it on track for a mid-2013 submission.
Somnus Therapeutics Inc.
Somnus Therapeutics is developing a timed-release formulation of zaleplon, a GABA agonist that is currently approved for short-term difficulty in falling asleep. According to company, its version of the drug is expected to offer patients an initial two hours of drug-free delta sleep, followed by the controlled release of a short-acting active ingredient, which may allow people to awaken more refreshed and alert.